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ABSTRACT 
Ring-necked pheasants are raised on farms under conditions similar to commercial 
production of broiler chickens and turkeys.  They are routinely infected with coccidia that 
cause outbreaks of clinical disease and sometimes death. Amprolium (Corid®) is the only 
approved drug for use against coccidiosis in this species and resistance has been reported. 
Lasalocid (Avatec®) is approved for use in broiler chickens, growing turkeys, and chukar 
partridges for the prevention of coccidiosis caused by Eimeria species specific for each of 
these birds. It is used extra-label on pheasant farms and has been demonstrated in controlled 
trials to be effective against coccidia that cause disease on pheasant farms.  In order to add 
pheasants to the Avatec® label, information regarding its efficacy and safety is required by 
the U.S Food and Drug Administration. The current work focused on target animal safety 
evaluation of lasalocid use in ring-necked pheasants. No treatment related effects were 
observed in physical, clinical pathologic and tissue evaluations when lasalocid was dosed 
orally at 1, 2 and 3 times the recommended high dose for treatment of coccidia in other avian 
species for 6 weeks, equivalent to 3 times the duration of treatment.
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CHAPTER 1. GENERAL INTRODUCTION AND LITERATURE 
REVIEW 
Thesis Organization 
This thesis comprises six chapters. Chapter 1 is a literature review that familiarizes the reader 
with background information about pheasants and coccidiosis as well as reasons why the 
research presented was performed. Chapters 2 and 3 report the target animal safety of 
lasalocid (Avatec®) when used in ring-necked pheasants at 1, 2 and 3 times  the label dose of 
other species of poultry for 6 weeks which is equivalent to three times the normal treatment 
length. Chapter 4 describes how reference intervals for clinical pathology parameters were 
determined. Chapter 5 discusses the results of the target animal safety evaluations. Chapter 6 
concludes this thesis and briefly highlights further investigations required to provide data that 
that will be considered towards the FDA approval of Avatec® in ring-necked pheasants. 
Chapters 2, 3 and 4 were adapted from manuscripts that will be submitted to the Journal of 
Avian Diseases. References cited are listed at the end of the thesis. 
Literature Review 
Pheasant background 
Ring-necked pheasants (Phasianus colchicus) are large gallinaceous game birds that occur 
worldwide but are native to central and eastern Asia (53). Those occurring in North America 
were first introduced in 1881 from China, achieving stable breeding populations in at least 35 
of the current 50 states by 1940 (28, 64).  They were noted for their palatability, attractive 
nature, and ability to adapt to any habitat as well as potential to reproduce and thrive in 
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captivity. They became even more desirable because they were relatively resistant to many 
parasites and other diseases common to domestically raised birds (63).  
In the last century, ring-neck pheasants have become an important source of meat and 
wildlife activities in the United States.  According to the U. S. Department of Agriculture 
(USDA), about 10 million pheasants are sold annually for human meat consumption (15). In 
comparison, 8 billion chickens, 220 million turkeys, 37 million quail, 4 million chukar 
partridges and 1 million mallard ducks are also sold locally for feeding humans and other 
animals (15, 44).  While the contribution by pheasants is small when compared to other 
poultry, they still represent an important sector to U.S. poultry production and wildlife-
associated recreation. In the most recent national survey by the U.S. Fish and Wildlife 
Service (USFWS), pheasants were the 5
th
 most hunted animal species in 2006 (after deer, 
wild turkey, leporids and squirrels), attracting 1.6 million hunters in a cumulative 12 million 
days. They contributed significantly to approximately $2.4 billion worth of spending on 
small game hunting compared to $11.8 billion spent on big game hunting (70). 
Changes in land use policies and agricultural practices in the last 100 years have led to the 
destruction of naturally occurring pheasant habitats and a consequent decline in their 
population (22). In order to increase their numbers, pheasants are now intensively raised on 
game farms under conditions similar to commercial poultry production (62). Under these 
systems, pheasants succumb to bacterial, viral and parasitic infections including 
salmonellosis, colibacillosis, coccidiosis, hexamitiasis, histomoniasis, syngamiasis,  avian 
encephalomyelitis and adenovirus amongst others (4, 23, 51, 59, 62, 72).  
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Coccidiosis 
Coccidiosis is a parasitic disease of the intestine of many animals caused by obligate 
intracellular protozoa (coccidia) belonging to the family Eimeriidae (32). Coccidia that cause 
illness in pheasants belong to the genus Eimeria (45, 59, 62). The most commonly 
encountered coccidia in outbreaks of clinical disease are Eimeria colchici, E. phasiani and E. 
duodenalis although E. tetartooimia has also been described (23, 42, 45).  At least six other 
species of Eimeria have been described in the literature and are reported to cause mild to 
severe disease (45, 49). Coccidiosis is most prevalent in pheasants between 2 and 6 weeks of 
age although younger and older birds can be affected (39). Outbreaks of coccidiosis in 
confined pheasants has been associated with overcrowding, poor sanitation and concurrent 
disease because these conditions favor high parasite reproduction (23). Cross infection with 
other species and birds has also been described (45). 
The life cycle of coccidia and pathogenesis of coccidiosis in pheasants is similar to that 
observed in other avian species (39). Briefly, oocysts are passed in feces of infected birds, 
sporulate and become infective under favorable conditions of temperature, oxygen and 
humidity. These sporulated oocysts are then ingested in feed, water, litter and/or soil. Once in 
the intestine, sporozoites invade the intestinal mucosa and develop into schizonts and 
merozoites. Merozoites invade adjacent cells until they develop into gametocytes and 
fertilize to produce oocysts that are passed out with feces and the cycle repeats itself (11).  
Coccidia invasion of the intestine is responsible for the observation of diarrhea, the character 
of which will vary from watery to mucohemorrhagic. In chronic cases, pheasants begin to 
lose weight, become dehydrated and eventually die. Severity of infection depends on the 
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Eimeria species involved and on the number of ingested sporulated oocysts. Although 
multiple species of Eimeria are usually isolated from farms undergoing active disease 
outbreaks (23, 45), fatal disease has been demonstrated experimentally when a single species 
is involved (24). Intestinal lesions caused by Eimeria in pheasants are similar to those 
reported for other birds (3, 27, 73). 
Treatment of coccidiosis is aimed at reducing  the severity of  clinical disease while allowing 
for the development of  immunity (46). Amprolium, a thiamine derivative, is the only U.S 
Food and Drug Administration (FDA) -approved drug for use in pheasants against 
coccidiosis. It is marketed by Merial Limited as Corid® (NADA 012-350), a type A 
medicated article, containing 25% amprolium. It is added to feed at 175 ppm as a continuous 
dose up to 8 weeks of age. Patton  et al., (1984), demonstrated the efficacy and safety of 
amprolium against E. colchici, E. duodenalis and  E. phasiani (50). They found that when 
they challenged 2 week old pheasant chicks with a high dose of infective oocysts, and 
subsequently fed medicated diets that contained 125 ppm, 175 ppm and 250 ppm amprolium, 
pheasant chicks receiving medicated diets did not die compared with those receiving a non-
medicated diet. No information regarding subsequent oocyst shedding was reported. While 
amprolium has been used for several decades, there have been  reports of reduced efficacy in 
the control of coccidiosis on intensively reared pheasant operations (47). 
Other methods such as immunization of pheasants using  sub-lethal oral doses of E. colchici 
oocysts (33) or treatment of E. colchici oocysts with ozone to inhibit sporulation (34) have 
been demonstrated to reduce the severity of clinical disease under battery trials but the 
efficacy of these techniques as well as the cost considerations are unknown at this time.  
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Classification of pheasants  
The U.S. Department of Agriculture (USDA) allows pheasants reared in captivity, not hunted 
in the wild, to be sold for human consumption (15). According to the U.S. Food and Drug 
Administration (FDA), birds, other than chickens or turkeys, are considered minor species 
(67) . Farm-reared pheasants are, therefore, classified as minor food-producing animals and 
use of drugs in this species must follow the same federal guidelines as for other food-
producing animals.  
Extra-label drug use (ELDU) 
Many of the diseases that occur on pheasant farms can be medically managed through the 
administration of medication in feed or water because this is practical and convenient. By 
law, the drug must be labeled for use in this species, and use of an unapproved animal drug in 
the feed of a food-producing animal, such as pheasants is prohibited. The number of FDA-
approved drugs available for use in game birds in general remains extremely low, with only 5 
for pheasants, 2 for chukar partridges, 3 for ducks and 8 for quail. In comparison at least 250 
medications are labeled for chickens and turkeys (44).  
Extra-label drug use (ELDU) in food-producing animals is acceptable under conditions 
described by the Animal Medicinal Drug Use Clarification Act (AMDUCA) (9, 14). ELDU 
in pheasants is acceptable under the same conditions as AMDUCA according to 
supplemental information described in the FDA’s Compliance Policy Guidance (66). The 
exceptions state that ELDU in feed is permitted under veterinary guidance for up to 6 months 
and the FDA “will not ordinarily consider regulatory action against a veterinarian” provided 
specific regulations are followed. The roles of veterinarians who prescribe suitable extra-
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label medications on pheasant farms are to create a valid veterinarian-client-patient 
relationship, determine the appropriate dose for the flock being treated, use a medication that 
is approved in at least one other major species, ensure appropriate labeling of feed, keep 
accurate records, confine the population and establish appropriate withdrawal period. In 
order for veterinarians to make treatment decisions, as well as remain within accepted legal 
practice, they require access to therapeutic drugs as well as scientific data that demonstrates 
effectiveness, target animal safety and potential drug residues remaining in edible animal 
tissues that could potentially enter the human food chain. The use of ionophores in pheasants 
is currently considered ELDU. 
Ionophores  
Ionophores are antibiotics produced by Streptomyces bacterial species. They were originally 
developed for poultry as coccidiostats but have been added to feed for many decades as 
growth promotants in ruminants (38). Ionophores possess a broad anticoccidial and 
predominantly gram positive antibacterial spectra.  They are classified as either channel 
formers or ion carriers. Channel forming ionophores aggregate within a cell membrane and 
create a hydrophilic channel across the membrane with hydrophobic residues outside the cell. 
In this way, various ions from outside a cell environment can be transported into a cell. Ion 
carriers (neutral or carboxylic), complex with monovalent and/or divalent ions forming lipid 
complexes that are then transported across surface membranes via passive diffusion (18). 
Ionophores commonly used in livestock production are lasalocid, monensin and salinomycin 
(6, 58). 
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Lasalocid 
Lasalocid is a carboxylic polyether ion carrier ionophore produced by the bacterium 
Streptomyces lasaliensis. It is used as a sodium salt (CAS No. 25999-20-6), and its structure 
as depicted by Ripoli et al., (54) is shown in Figure 1. Lasalocid is unique in that it facilitates 
the transport of both monovalent (H
+
, Na
+
 and K
+
) as well as divalent (Ca
2+
and Mg
2+
) cations 
across cell surface membranes (18). Other molecules such as norepinephrine and epinephrine 
can be complexed in vitro to lasalocid, allowing them to be transported across surface 
membranes. Because of this, lasalocid has been used by physiologists and biochemists to 
study transport  mechanisms in various membrane systems (18). Lasalocid is marketed by 
Pfizer Animal Health as Avatec®, a type A medicated article containing 20% lasalocid 
sodium. 
The effect of lasalocid on coccidia has been studied in chicken-specific Eimeria species (E. 
tenella and  E. acervulina) using light and electron microscopy (8, 43).  Lasalocid increases 
the osmolality in 1
st
 and 2
nd
 generation extracellular sporozoites and merozoites, causing 
them to absorb water and consequently rupture. Intestinal mucosa invasion and oocyst 
shedding are reduced (36). At 75, 90, 100 and 125 ppm, Bains (1980) showed that lasalocid 
was effective against major coccidia species in chickens (2). In pheasants, lasalocid has been 
shown to be more effective against major coccidial species at 75 ppm and 120 ppm compared 
to other ionophores such as monensin and salinomycin (29, 41). 
Lasalocid toxicity 
In general, lasalocid and other ionophores are safe in poultry and ruminants if administered at 
recommended doses. Numerous reports are available on the toxicity of lasalocid in various 
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species (17). Most toxicity issues are encountered following accidental ingestion, overdosing 
and/or feed mixing errors (20, 48). Once absorbed, lasalocid is distributed into muscle, liver, 
skin, fat, heart, thymus, lung and spleen.  Peak plasma concentrations in chickens can be 
obtained within 2 hours after administration, while about 95% remains in the intestines and is 
excreted in feces. Signs of toxicity will vary but result from the disruption of normal 
physiologic ionic gradients. Cardiac and skeletal muscles appear to be the most sensitive 
organs. 
Reduced weight gain, mortality, reduced fertility and hatchability were described by 
Perelman (1993) when broiler chickens were accidentally fed 115 and 150 ppm  (52). 
Ionophore-induced neurotoxicity has also been reported where birds become ataxic and have 
leg weakness (12, 30). Death can either be due to heart failure as a result of myocardial 
necrosis or in chronic cases, low caloric intake associated with inappetence and anorexia 
(25). McDougald and McQuistion (1980) demonstrated that temporary compensatory growth 
can occur within a week of toxicity if anticoccidial drugs are removed from feed (40).  
Information regarding the effect of lasalocid and other ionophores on clinical pathology 
parameters in poultry is lacking. In one study, 5-week old chickens that were treated with 
300 or 400 ppm monensin for 16 days had elevated serum levels of aspartate 
aminotransferase, lactate dehydrogenase,  malate dehydrogenase, creatine phosphokinase and 
malic enzyme detected in serum (26).  The observed enzyme elevations were suggestive of 
cardiac muscle, skeletal muscle and liver dysfunction, but these were not accompanied by 
any observable clinical signs similar to observations in cattle and horses. No tissue gross or 
microscopic evaluations were reported. In another study, lasalocid had no effect on serum 
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glucose, triglycerides, cholesterol, total proteins and albumin, estradiol and progesterone 
levels when administered continuously through feed to turkey poults until they were 23 
weeks old (55).  
Current use of lasalocid 
Lasalocid sodium (Avatec®) is approved for use in broiler or fryer chickens, growing 
turkeys, and Chukar partridges for the prevention of coccidiosis caused by a variety of 
Eimeria species specific for each of these animals (NADA 096-298). As a feed additive, it is 
given continuously to growing turkeys, broiler and fryer chickens at a dose of 68 ppm to 113 
ppm and 113 ppm to chukar partridges from day 0 up to 8 weeks of age with no withdrawal 
period required. The use of Avatec® in ring-necked pheasants is ELDU. No scientific 
information is available regarding safety of this medication in this species or potential tissue 
residues that may inadvertently end up in the human food chain.  
In ruminants lasalocid is marketed as Bovatec® (NADA 096-298). Its primary use is to 
improve weight gain and feed efficiency through altering ruminal microbial populations 
towards gram negative bacteria that increase propionic acid production and reduce acetate. In 
doing so, it 1) increases glucose that enters the blood stream; 2) conserves energy and amino 
acids. In addition to this, it improves magnesium, phosphorous, zinc, and selenium 
absorption, nutrients that are vital for energy and efficiency in ruminants (57). Bovatec® also 
has anticoccidial properties against Eimeria bovis and  E. zuernii (61).  It has been used in an 
extra-label manner in calves against Cryptosporidium parvum (5), although it is virtually 
ineffective against this organism. 
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FDA drug approval process 
The Center for Veterinary Medicine (CVM) is the division of the FDA that governs the 
evaluation and approval of all animal pharmaceuticals, medicated feeds and animal devices. 
Prior to approval, the FDA/CVM requires that a new animal drug application (NADA) be 
submitted. The NADA must provide evidence that the drug is safe and effective for its 
intended use, and that the methods, facilities and controls used for manufacturing and 
packaging of the drug are adequate to preserve its identity, strength and quality.  
Obtaining FDA approval for a drug is a lengthy and expensive process. The cost of obtaining 
information for FDA approval for a new animal drug is estimated between $10-$25 million 
and can take between 7 and 10 years depending on the nature of investigations required to 
obtain necessary data (68). Even after the studies are complete and the drug is approved, 
there are expenses associated with label changes, annual reports and adverse event 
monitoring.  While most investigations aimed at providing data for a particular NADA can 
be performed by independent researchers, studies are typically sponsored by pharmaceutical 
companies that are heavily invested in the financial returns. In major species, the returns are 
high enough to be able to recover the costs incurred in investigating new animal drugs. 
In a species such as pheasants, the market size is not large enough to guarantee sufficient 
economic return to a pharmaceutical sponsor. It may be less expensive to add pheasants to an 
existing label through providing supplemental information regarding safety and effectiveness 
of a product already on the market. Even with this provision, the cost of adding a new species 
to a label is between $2 and $8 million (average of $3.1 million) and research aimed at 
acquiring data for the label claim can take over 3 years (68).  
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To help facilitate the development of drugs for minor species, the Minor Use and Minor 
Species Animal Health Act was passed in 2004. Under this law, pharmaceutical companies 
were allowed to conditionally market a drug for use in minor species while providing 
additional time to collect efficacy and safety data. Federal funding was set aside for studies 
aimed at reducing the costs to complete investigations required by the FDA/CVM. The 
procedures investigators would need to follow towards adding a minor species to an existing 
label are regulated by the Office of the Minor Use/Minor Species (OMUMS) and the Office 
of New Animal Drug Evaluation (ONADE). Support for controlled research in minor food 
animal producing species is provided by National Research Support Projects (NRSPs) that 
have been facilitated by the USDA. According to the NRSP-7 2009 annual report, there are 
currently over 343 drug requests have been submitted to  OMUMS for investigation, with 
about 40 of those drugs identified as urgently needed in minor species (68). 
Studies aimed at providing data for safety evaluation of lasalocid in pheasants must be 
conducted under Good Laboratory Practices (GLP) for nonclinical laboratory studies. The 
requirements are codified under Title 21, Code of Federal Regulations Part 58 (21CFR Part 
58) (69). The following is an overview of the drug approval process as it relates to lasalocid 
for its use in pheasants. 
Investigational new animal drug (INAD) exemption 
The INAD exemption requires that, prior to beginning research; investigators must receive 
FDA approval to administer the drug for experimental purposes in the intended species. In 
their application, they must propose the drug product, the label indications and the target 
animal in which the drug is to be used in. The investigator and the FDA/CVM then agree on 
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a product development plan that outlines requirements and conditions for the safety and 
efficacy trials.  
New animal drug application (NADA) information 
Once safety and efficacy information is acquired, it is then compiled and submitted as an 
original NADA or supplement to an existing NADA that seeks to add a species to a particular 
label.   
Efficacy 
The objective of an efficacy trial is to demonstrate that a drug is effective towards or against 
the condition for which its use is intended. This can be demonstrated in vitro or in vivo using 
laboratory animals or in the target species. Ideally, one would to simulate conditions that 
mimic natural infection and demonstrate a drug’s potency against known isolates of the 
disease-causing agent within the host.  
McQuistion was the first to report the efficacy of lasalocid against 4 Eimeria species, E. 
phasiani, E. pacifica, E. duodenalis and E. tetartooimia in pheasants (42). He administered 
coccidial suspensions to 3-week-old pheasant chicks, and then gave medicated feed 
containing 120 ppm lasalocid, salinomycin or monensin to each group of pheasants. While he 
observed a decreased mortality rate and significantly reduced oocyst shedding in all 
medicated birds, pheasants receiving lasalocid shed the lowest number of oocysts and had the 
highest weight gain per any of the groups. Fuller et al., (16) also showed that lasalocid at 
120 ppm decreased oocyst shedding and improved weight gain 5 days after pheasants were 
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inoculated with mixed coccidian isolates containing E. phasiani, E. duodenalis, and E. 
colchici. 
Target animal safety (TAS) 
The objective of a target animal safety evaluation is to investigate potential undesirable side 
effects in the target animal that could be attributed to the administration of a particular drug. 
FDA/CVM requires that the drug be tested at the claimed effective dose and progressively 
higher doses for an extended period of time beyond the duration a drug would ordinarily be 
used.  The test subjects must be observed periodically for any harmful effects, including 
death, associated with these overdoses and/or increased duration of administration. Criteria 
for assessing safety should be indicated and should include but are not limited to clinical 
observations, clinical pathologic and gross and microscopic tissue evaluations. 
Human food safety (HFS) 
Human food safety is assessed through determining whether a drug, its metabolites or any 
other compounds formed as a result of use of that drug are detectable in edible tissues of that 
animal species. Ideally, levels must be non-detectable, below or within the allowable 
tolerances determined for other major avian species. Assessing tissue residues also requires 
knowledge of drug metabolism within the host animal. The goal is to establish a drug 
withdrawal period to ensure consumer safety. Methods used to analyze these tissue residues 
should be extremely accurate with a high level of sensitivity and specificity.  High 
performance liquid chromatography (HPLC) has been used to determine lasalocid residues in 
chicken and turkey edible tissues. Tolerance levels established are; chicken skin and fat at 1.2 
ppm, chicken liver at 0.4 ppm, turkey skin and fat at 0.4 ppm, and turkey liver at 0.4 ppm. 
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While the same analytical method can be applied to pheasant tissues, it must be bridged to 
pheasant tissues and validated by assessing specificity, linearity, recovery, accuracy, 
precision, limit of detection, limit of quantification and stability of extracts.  
Pheasant edible tissues include muscle, liver, muscle fat, kidney and skin. Lasalocid is not 
known to break down into other compounds nor generate metabolites. Although lasalocid is 
known to be toxic to other animals when administered at high enough doses there are no 
reported cases of toxicity in humans, nor is it used in human medicine. Case reports are 
available for monensin and salinomycin in which patients died shortly after exposure (31, 
60). Furthermore, it could still be absorbed into the circulatory system and exert cardiac 
and/or skeletal damage via similar mechanism as those in animals. Fortunately, levels in 
other species have remained sufficiently low that they have never been a threat to consumers 
(10) 
Conclusion 
Coccidiosis remains a significant threat to the welfare of farm- raised pheasants between the 
ages of 2 and 6 weeks. Most disease outbreaks are accompanied by diarrhea, dehydration, 
reduced feed intake, reduced weight gain, and sometimes death. Amprolium (Corid®) is 
currently the only drug on the market labeled for use for the prevention of coccidiosis caused 
by E. colchici, E. phasiani and E. duodenalis in growing ring-necked pheasants.  
Unfortunately resistant isolates have been reported on some farms. Lasalocid sodium 
(Avatec®) is effective against several field isolates of Eimeria species that infect ring-necked 
pheasants. It is approved for use in broiler chickens, fryer chickens, growing turkeys and 
chukar partridges for the prevention of coccidiosis specific to those species. Lasalocid is used 
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extra-label in pheasants and other game birds such as quail and mallard ducks that succumb 
to coccidiosis as well. Based on reports of its efficacy and its application in other poultry 
species, Avatec® may have a clinical application in the management of coccidiosis on 
pheasant farms. Before pheasants can be added to the Avatec® label, Avatec must meet the 
NADA requirements that demonstrate its safety in both the target species and in humans that 
may consume pheasant tissues. The target animal safety evaluation of Avatec® is presented 
in this thesis in partial fulfillment of NADA requirements for adding pheasants to the drug 
label. 
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Figure 2. Chemical structure of lasalocid sodium (54). 
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CHAPTER 2. SAFETY EVALUATION OF LASALOCID USE IN RING 
NECKED PHEASANTS (PHASIANUS COLCHICUS) 
Modified from a paper to be submitted to the Journal for Avian Diseases 
Dzikamunhenga R.S., Wilberts B., Yaeger M., Bender H., Larson W., and Griffith R.W. 
Abstract 
The objective of the study was to gather data on the safety of lasalocid when fed to pheasants 
at levels of 0, 125, 250 and 375 ppm. These levels are equivalent to 0X, 1X, 2X and 3X the 
label dose for prevention of coccidiosis in broiler chickens, fryer chickens, chukar partridges 
and growing turkeys. One hundred and sixty pheasant chicks that were one day-old were 
randomly blocked by sex into 4 treatment groups.  Group 1 pheasants (n=40) received a non-
medicated basal diet and served as controls.  Group 2 (n=40), Group 3 (n=40) and Group 4 
(n=40) received a medicated diet that contained 125 ppm, 250 ppm and 375 ppm of lasalocid, 
respectively. Fresh feed was provided to all pheasants once daily for 6 weeks. Two pheasants 
(1.25%) were observed to be moribund and were humanely euthanized prior to study 
termination. Their illnesses were not related to lasalocid treatment. When the pheasants were 
6 weeks old, they were humanely euthanized. Blood was collected for hematologic and 
serum biochemistry analyses. Necropsy and histopathologic evaluations were performed on 
the pheasant tissues. No adverse clinical signs related to the intake of lasalocid were 
observed during the six weeks of feeding. Liver weights were significantly higher for 
pheasants in the 2X and 3X groups when compared to controls. Red blood cell counts, 
packed cell volumes and alkaline phosphatase enzyme levels were significantly lower for 
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pheasants in the 3X group compared to controls. Female pheasants in the 3X group had 
significantly higher mean values for blood monocyte counts, total protein and calcium when 
compared to controls. Female pheasants in the 2X group had significantly higher serum 
calcium levels compared to controls. Collectively, these observations were of small 
magnitude, did not appear to be accompanied by other clinical or tissue reactions and/or were 
within established reference intervals such that they were considered incidental. No 
significant differences were observed in live weights; overall feed consumption; feed 
conversion rates; other clinical pathology variables; or gross and histopathologic tissue 
evaluations when treatment groups were compared to controls. The results of this study show 
that lasalocid fed at 1X, 2X and 3X the label dose for control of coccidia in other avian 
species is safe in ring-necked pheasants. 
Introduction 
Pheasants are raised on propagation farms in several states under conditions similar to the 
commercial production of poultry.  They are routinely infected with coccidia such as Eimeria 
colchici, E. duodenalis, E. phasiani with outbreaks of clinical disease and sometimes high 
mortality being reported (23). Fatal infections are highest between 2 and 6 weeks of age and 
results in severe economic losses. Amprolium, a thiamine derivative, is currently the only 
drug approved for use in prevention of coccidiosis in growing pheasants. It is safe and 
effective at a dose of 175 ppm (50). Unfortunately, it has a limited species activity spectrum 
and resistant strains have been reported on some farms (46). 
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Lasalocid is a divalent carboxylic ionophore that facilitates the movement of monovalent and 
divalent ions across cell surface membranes (18). Lasalocid used in commercial operations is 
marketed as a sodium salt (Avatec®) and is labeled for use in broiler chickens, growing 
turkeys, and chukar partridges for the prevention of coccidiosis caused by a variety of 
Eimeria species specific for each of these birds. Lasalocid has been demonstrated to be 
effective against Eimeria species on pheasant farms at 120 ppm in feed (16, 42). Use of 
lasalocid on pheasant farms is extra-label and is acceptable under the Animal Medicinal Drug 
Use Clarification Act (AMDUCA) guidelines according to supplemental information 
described in the FDA’s Compliance Policy Guidance (44).  Before lasalocid can be approved 
by the U. S. Food and Drug Administration (FDA), information regarding its efficacy and 
safety must be documented in controlled trials.  The objective of this study was to gather data 
on the safety of lasalocid when fed to pheasants from 0 to 6 weeks of age. It was 
hypothesized that no toxic effects would be associated with lasalocid administration.  
Materials and Methods 
Pheasants 
One hundred and sixty Chinese ring-neck pheasant chicks (Phasianus colchicus) were 
purchased from Oakwood Game Farm (Princeton, MN). There were 80 males and 80 
females. Pheasant chicks were one day old at study initiation and 6 weeks old at study 
termination.  
Pheasant housing and maintenance 
Pheasants were housed at a research facility at the Iowa State University Poultry Science 
Farm (Ames, IA). No acclimation period was used and pheasant chicks were placed in the 
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experiment on the day of arrival. Pheasants were raised in floor pens that measured 1.22 
meters x 1.22 meters x 1.22 meters separated by wire partitions. Heat lamps suspended 
approximately 0.35 meters were used to provide artificial heat and light for the pheasant 
chicks up to 2-weeks of age. Once heat lamps were removed, room lighting was the only 
source of light for the pheasants.  Pheasants were provided with approximately 16 hours of 
light and 8 hours of darkness per day. Wood shavings were used as bedding and were 
replenished as needed to maintain a sanitary and comfortable environment.  
Treatment and control group layout 
Pheasant chicks were blocked by sex and randomly assigned to four test groups of 40 
pheasants each (20 males and 20 females).  Eight pens (replicates) were used per test group 
and each pen housed 5 pheasants. There were a total of 32 pens of pheasants.  
Test article and diet formulation 
The basal diet used was a commercial starter preparation, Game Bird Startena
TM
 (Purina ®), 
formulated to meet the nutritional requirements of pheasants from 0 to 6 weeks old. 
Lasalocid (Avatec®) was obtained from Alpharma Inc., (Bridgewater, NJ) as a premix with 
20% (199.54 g per kilogram) lasalocid sodium. Lasalocid was formulated for mixing with the 
basal diet using the following formula: 
Dose (mg/kg)x Weight of basal diet (kg) 
= Test Article Dose (g) of premix per 45.4 kg 
bag of premix Concentration of lasalocid (g lasalocid/g premix) 
 
Approximately 0.5 kg of the medicated feed was collected from each prepared batch and 
submitted to Alpharma Inc., for assay at study initiation and at study termination.  
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Experimental design 
There were 4 test groups in this investigation. Table 1 shows the formulation of the 4 test 
group diets. No lasalocid was added to the diet fed to the pheasants in test group 1 which 
were the controls. Pheasants in test groups 2, 3, and 4 were fed the basal diet with 
approximately 125 ppm, 250 ppm and 375 ppm lasalocid added, respectively.  These doses 
were equivalent to 1X, 2X and 3X the approved dose of lasalocid in broiler or fryer chickens, 
growing turkeys, and Chukar partridges. Fresh feed was provided to the pheasants once daily 
for 6 weeks.  Water was provided ad libitum via automatic drip tubes. Blinding was 
maintained by ensuring that persons that were involved at each level of clinical or pathologic 
evaluations had no knowledge of dosing. All phases of this study were conducted under 
Good Laboratory Practices (GLP) (21 CFR Part 58) guidelines for nonclinical laboratory 
studies, and were approved by the Institutional Animal Care and Use Committee (IACUC) of 
Iowa State University. Critical phases were monitored by quality assurance personnel 
appointed by the Minor Use Animal Drug Program (MUADP),  National Research Support 
Porject-7 (NRSP-7). 
Clinical observations 
Study inclusion physical examinations were conducted by a veterinarian on each pheasant on 
day 0, and only normal and healthy pheasant chicks were included in the study. Pheasants 
were observed twice daily throughout the study to determine their general appearance as well 
as monitor consistency of fecal output, death and/or normal conditions. Pheasant general 
appearance for each pen was scored as 6=very excitable/agitated; 5=slightly agitated, 
excessive vocalization; 4=normal; 3=slight depression, feathers slightly ruffled, does not 
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appear to be gaining weight; 2=marked depression, ruffled feathers, obvious anorexia and 
1=dead.  Feces were described as one of the following: 5=severe watery diarrhea that may 
contain mucus and/or blood; 4=moderate diarrhea that may contain some mucus and/or 
blood; 3=slight diarrhea; 2=slight change from normal and 1=normal. A veterinarian 
confirmed any unusual observations. Moribund and/or dead pheasants were removed and 
necropsied. The chicks were weighed as a group at the time of placement into pens and 
individually at euthanasia at 6 weeks of age.  
Feed consumption and feed efficiency 
Fresh feed was weighed daily prior to being fed to pheasants. Feed remaining in feed 
containers or that may have inadvertently spilled during the day or night was noted in the 
morning, weighed and discarded. Food consumption and feed efficiency were determined 
and reported as average of the pen at the end of the study.  The following formula was used 
to calculate adjusted feed conversion rate: 
Total feed disappearance 
[(total terminal pen bird weight + all dead and removed bird weights) – total bird weights in the pen at day 0] 
 
Total feed disappearance (feed consumption) was defined as the sum of all feed additions to 
a pen minus the sum of all feed weighed back from that pen and the estimated or actual 
wastage. 
Hematology and serum chemistry 
At 6 weeks, pheasants were randomly sacrificed by direct intramuscular injection of 
pentobarbital solution into the breast muscle. As soon as the birds were unconscious and 
prior to cardiac arrest, approximately 2 ml of blood was collected via the vena cava.  The 
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blood was divided between EDTA and heparinized vacutainer tubes and submitted to the 
Iowa State University, Veterinary Clinical Pathology Laboratory for hematology and serum 
biochemistry analyses. The following hematology variables were determined: red blood cell 
count; packed cell volume; mean corpuscular volume; white blood cell count; heterophils; 
eosinophils; lymphocytes; monocytes and thrombocyte counts.  The following serum 
biochemistry values were determined: glucose, total protein; albumin, creatine kinase, 
aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, calcium, 
phosphorous, sodium, potassium, chloride, magnesium, amylase, uric acid, lactate 
dehydrogenase, alkaline phosphatase, total bilirubin, cholesterol and globulin. 
Organ weights, necropsy and histopathology 
Organ weights were obtained on heart, liver, spleen and thymus of the sacrificed birds. The 
following organs and tissues were examined grossly and histologically for any lesions or 
abnormalities: skin, eyes, liver, kidney, heart, lungs, trachea, adrenal gland, pancreas, 
esophagus, crop, spleen, proventriculus, ventriculus, intestines (upper, middle and cecum), 
bursa of fabricius, ovaries and oviducts, testes, bone, thyroid gland, thymus, parathyroid 
land, brain, spinal cord and pituitary body.  If lesions were noted on gross necropsy, a full 
description was made and tissues collected for histologic examination. If no lesions were 
present, a representative sample of tissues was collected for histologic examination. The 
selected tissues were preserved in 10% neutral buffered formalin and prepared as paraffin-
embedded sections on glass microscopic slides. Hematoxylin and eosin stained sections of 
the tissues were examined by light microscopy. Necropsy and histopathologic examinations 
were performed by a board-certified veterinary anatomic pathologist. 
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Data analyses 
Primary variables for statistical analyses were morbidity, mortality, live weights (beginning 
and ending pen weights), organ weights, hematology and serum biochemistry parameters, 
food consumption and feed conversion rates. Statistical analyses were performed using SAS 
Enterprise Guide statistical software (version 4.3; SAS Institute, Inc., Cary, NC, USA). A 
mixed effect two way analysis of variance (ANOVA) was performed on the live weights, 
organ weights, organ/body weight ratios, feed consumption data, serum chemistry and 
hematology data. “Individual pens” was considered the random effect. There were no 
additional random effects. Test group and sex, and the interaction of test group and sex were 
considered fixed effects. There were no additional fixed effects. Least square means were 
used to compare the treated test groups to the control test groups. No adjustment of p-values 
was made. All statistical tests were conducted at 0.1 level of significance to meet the U.S 
Food and Drug Administration (FDA) protocol specifications evaluating effects of lasalocid 
administration. Feed conversion rates were calculated in Microsoft© Excel©. No statistical 
analyses were made for necropsy and histopathology.  
Results 
Diet analyses 
Analyses performed on each dietary treatment group to confirm the target test article 
composition are shown in Table 1. Lasalocid was incorporated into three out of four test 
group diets. Beginning and ending trial composition for diets 1, 2 and 3 and the beginning 
trial composition for diet 4 were slightly higher than the targeted concentrations and 
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considered to be within ± 20% tolerance. The ending feed analysis of diet 4 was only slightly 
above the approved ±20% tolerance dose that had been targeted. 
Pheasant observations, morbidity and mortality 
One hundred and fifty eight out of one hundred and sixty pheasants received their intended 
doses for the entire six weeks. Two pheasants were observed to be moribund on days 17 (2X 
group) and 27 (3X group) respectively and these were humanely euthanized. Gross necropsy 
and histopathology of these pheasants revealed that the first bird had a generalized bacterial 
infection and the second bird had a dislocation of the spinal cord between cervical vertebrae 
C3 and C4.  These deaths were not attributed to lasalocid administration. All other pheasants 
appeared to be in good health for the duration of the study and no other unusual or otherwise 
noteworthy findings were observed. The 1.25% mortality rate observed was within historical 
values of the facility. No statistical analyses were necessary for the variables morbidity and 
mortality.  
Live weights 
Mean test group pheasant weights at study initiation and termination are shown in Table 2. 
All pheasants gained weight over the course of the study. No significant difference in the 
mean ending body weights were seen when controls were compared to treatment groups 
(p=0.2287).  
Feed consumption 
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The average amount of feed consumed per test group is shown in Table 2. There was no 
significant difference in mean food consumption (p=0.9094) were seen when controls were 
compared to treatment groups. 
Feed conversion  
Feed conversion data is used to assess the amount of feed required for weight gain when 
reported as grams of feed per gram weight gain. The mean feed conversion rate, corrected for 
body weight, by test group for the control and each treatment group is shown in the Table 2. 
No significant difference was found in mean feed conversion rates (p=0.5563) amongst the 
test groups. 
Organ weights 
Test group mean terminal organ weights are shown in Table 2. Mean liver weights were 
significantly higher for pheasants in the 2X (8.65 g, p) and 3X (8.61 g) groups compared to 
those in controls (7.88 g).  No other significant differences were observed in weights of other 
organs or organ to body weight ratios in any lasalocid treatment groups. 
Hematology and serum biochemistry 
Hematology and serum biochemistry test group means are summarized in Table 3. Males had 
higher mean monocyte counts and higher total protein and calcium values when compared 
with female pheasants.  Red blood cell counts and packed cell volumes (PCV) were lower for 
pheasants in the 1X, 2X and 3X groups compared to controls. Alkaline phosphatase enzyme 
levels were also significantly lower for pheasants in the 3X group when compared to 
controls. 
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Necropsy and histopathology 
One pheasant, in the 3X group had moderate subacute myocardial hemorrhage, necrosis and 
mineralization of the myocardium that could have been associated with lasalocid toxicity. 
Microscopically, mild focal lymphocytic and heterophilic infiltrates were seen on various 
tissues including myocardium, kidneys, lungs and spleens. These lesions were spread out 
amongst all birds.  
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Table 1. Test group diet analyses reported by Alpharma Inc. 
Diet 
Target dose 
g/t (ppm) 
Pre-trial lasalocid 
analysis  
g/t (ppm) 
Post-trial lasalocid 
analysis 
g/t (ppm) 
Control 0 (0) <0.5 (0) <0.5 (0) 
1X 113 (125) 133.6 (147) 110.3 (122) 
2X 204 (250) 231.8 (256) 244.7 (270) 
3X  340 (375) 424.7 (468) 272 (300) 
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Table 2. Test group means and standard deviations (SD) for live weights, organ and 
weights overall feed consumption and feed conversion rates. 
Variable 
Control 1X Group 2X Group 3X Group 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Beginning body weight 90.38 (2.77) 90.13 (1.73) 93.50 (4.72) 88.63 (5.15) 
Ending body weight 358.50 (43.95) 368.41 (46.80) 372.85 (47.44) 362.48 (51.30) 
Feed consumption 3992.63 (254.05) 4024.25 (385.63) 4054.00 (456.73) 4114.38 (333.66) 
Feed conversion rate 2.35 (0.08) 2.36 (0.09) 2.35 (0.07) 2.39 (0.07) 
Liver weight 7.88 (1.07) 8.28 (1.04) 8.65 (1.18)* 8.61 (1.30)* 
Heart weight 1.69 (0.29) 1.81 (0.28) 1.78 (0.27) 1.80 (0.27) 
Spleen weight 0.25 (0.08) 0.33 (0.14) 0.32 (0.13) 0.34 (0.12) 
Thymus weight 1.22 (0.40) 1.34 (0.39) 1.36 (0.30) 1.37 (0.44) 
 
*indicates significant difference at p<0.10 observed between controls and lasalocid treated pheasants.  
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Table 3. Test group means and standard deviations (SD) from clinical pathology sample 
testing performed in controls and pheasants treated with lasalocid sodium. 
Variable (units) 
Control 1X 2X 3X 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
RBC (x10
6
/µl) 3.05 (0.52) 2.87 (0.41) 2.77 (0.41)* 2.72 (0.31)* 
PCV (%) 35.86 (2.44) 34.30 (2.17)* 34.34 (2.89)* 33.87 (2.45)* 
MCV (fl) 120.27 (17.01) 121.85 (17.43) 126.23 (17.62) 125.60 (11.85) 
WBC (x10
3
/µl) 9.07 (4.96) 8.24 (4.45) 9.4 (4.33) 11.17 (9.38) 
-Heterophils (x10
3
/µl) 2.81 (3.27) 1.99 (2.43) 2.01 (2.23) 3.86 (6.80) 
-Eosinophils (x10
3
/µl) 0.05 (0.09) 0.07 (0.10) 0.07 (0.12) 0.08 (0.13) 
-Basophils (x10
3
/µl) 0.49 (0.42) 0.60 (0.32) 0.58 (0.35) 0.63 (0.39) 
-Lymphocytes 
(x10
3
/µl) 
5.60 (3.22) 5.45 (3.29) 6.39 (2.72) 6.04 (3.29) 
-Monocytes (x10
3
/µl) 0.20 (0.21) 0.17 (0.16) 0.34 (0.48) 0.56 (1.24) 
Glucose (mg/dl) 344.60 (26.32) 344.05 (36.76) 349.26 (30.48) 340.75 (25.77) 
TP (mg/dl) 2.82 (0.24) 2.84 (0.23) 2.86 (0.26) 2.92 (0.46)  
Albumin (mg/dl) 1.44 (0.15) 1.42 (0.10) 1.43 (0.13) 1.42 (0.13) 
Creatine kinase (IU/L) 3376.40 (941.28) 3395.92 (1379.59) 3199.92 (926.82) 2896.08 (801.91) 
AST (IU/L) 402.43 (93.11) 371.47 (57.27) 362.38 (42.79) 374.05 (48.93) 
ALT (IU/L) 7.33 (6.12) 6.87 (3.24) 5.49 (1.90) 6.55 (4.21) 
GGT (IU/L) 4.20 (1.70) 4.08 (1.94) 3.74 (1.73) 3.93 (1.56) 
Calcium (mg/dl) 10.01 (0.57) 9.88 (0.94) 10.37 (0.58) 10.29 (0.87) 
Phosphorous (mg/dl) 9.76 (1.91) 9.19 (1.98) 9.20 (1.28) 8.40 (0.92) 
Sodium (mEq/L) 153.33 (3.00) 152.44 (2.16) 153.13 (2.96) 152.93 (2.53) 
Potassium (mEq/L) 4.26 (1.54) 4.08 (1.50) 3.55 (0.92) 3.43 (0.74) 
Chloride (mEq/L) 112.08 (2.15) 112.13 (2.32) 111.56 (3.00) 111.93 (2.68) 
Magnesium (mg/dl) 2.53 (0.27) 2.42 (0.30) 2.52 (0.28) 2.40 (0.23) 
Amylase (mg/dl) 2582.83 (856.96) 2607.03 (680.19) 2421.33 (657.68) 2438.48 (627.80) 
Uric Acid (mg/dl) 20.41 (8.47) 15.12 (6.07) 18.43 (6.81) 16.06 (7.87) 
LDH (IU/L) 776.25 (328.70) 683.92 (174.04) 660.42 (136.33) 649.60 (196.99) 
ALP (IU/L) 1286.68 (269.31) 1205.21 (242.75) 1211.74 (221.95) 1044.75 (259.68) 
Total bilirubin (mg/dl) 0.21 (0.10) 0.25 (0.15) 0.26 (0.17) 0.26 (0.19) 
Cholesterol (mg/dl) 104.23 (14.94) 111.55 (13.58) 108.18 (15.88) 112.08 (16.71) 
Globulin (mg/dl) 1.36 (0.20) 1.42 (0.18) 1.78 (2.05) 1.49 (0.44) 
Variables: RBC, red blood cell count; PCV,  packed cell volume; MCV, mean corpuscular volume; WBC, white 
blood cell count; heterophils; eosinophils; lymphocytes; monocytes; glucose, TP, total protein; albumin, CK, 
creatine kinase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl 
transferase; calcium; phosphorous; sodium, potassium; chloride; magnesium; amylase; uric acid; LDH,  lactate 
dehydrogenase; ALP, alkaline phosphatase; total bilirubin, cholesterol and globulin 
*indicates significant difference at p<0.10 observed between treatment group and controls. 
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CHAPTER 3. SAFETY EVALUATION OF LASALOCID USE IN RING 
NECKED PHEASANTS (PHASIANUS COLCHICUS) 
Modified from a manuscript to be submitted to the Journal for Avian Diseases 
Dzikamunhenga R.S, Wilberts B, Yaeger M., Bender H., Larson B., and Griffith R.W 
Abstract 
The objective of the study was to gather additional data on the safety of lasalocid (Avatec®) 
when fed to pheasants at levels of 0 and 375 ppm for 6 weeks. These levels are equivalent to 
0X and 3X the label dose for prevention of coccidiosis in broiler chickens, fryer chickens, 
chukar partridges and growing turkeys. In the earlier study, feed samples were submitted to 
Alpharma Inc. following completion of the trial. The highest dose diet (3X) was found to be 
only marginally higher than the dose that had been targeted. It was decided to repeat the trial 
with only the 3X group and controls. Eighty pheasant chicks that were one day-old were 
randomly blocked by sex into 2 treatment groups.  Group 5 pheasants (n=40) received a non-
medicated basal diet and served as controls.  Group 6 pheasants (n=40) received a medicated 
basal diet that contained 375 ppm of lasalocid. Fresh feed was provided to all pheasants once 
daily for 6 weeks. Two pheasants (2.50%) died prior to study termination. Their illnesses 
were not related to lasalocid treatment. When the pheasants were 6 weeks of age, 48 (3 per 
pen) pheasants were randomly selected and humanely euthanized. Blood was collected for 
hematologic and serum biochemistry analyses. Necropsy and histopathologic evaluations 
were performed on the pheasant tissues. No adverse clinical signs related to lasalocid intake 
were observed during the follow-up period. No significant differences were observed in live 
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weights; overall feed consumption; feed conversion rates; clinical pathology variables; or 
gross and histopathologic tissue evaluations when the treatment group was compared to 
controls. The results of this study show that lasalocid fed at 3 times label dose of lasalocid for 
the prevention of coccidiosis in broiler chickens, fryer chickens, chukar partridges and 
growing turkeys, is safe for ring-necked pheasants. 
Materials and Methods 
Forty male and forty female pheasant chicks (Phasianus colchicus) that were one day old 
were enrolled in this study. Pheasant chicks were blocked by sex and randomly assigned to 
two test groups of 40 pheasants each (20 males and 20 females).   Control pheasants were fed 
a commercial non-medicated basal diet whereas pheasants in 3X group were fed the same 
commercial diet containing approximately 375 ppm of lasalocid sodium. Table 1 shows 
beginning and ending lasalocid analyses for the diets. Fresh feed in measured amounts was 
provided to the pheasants once daily for 6 weeks.  Water was provided ad libitum via 
automatic drip tubes. Pheasants were observed twice daily throughout the study to determine 
their general appearance as well as monitor consistency of fecal output, death and/or 
abnormal conditions. The chicks were weighed as a pen at the time of placement into pens 
and individually at 6 weeks of age.  
At 6 weeks, pheasants were randomly sacrificed by direct intramuscular injection of 
pentobarbital solution into the breast muscle. When pheasants were unconscious and before 
cardiac arrest, blood was collected and submitted for red blood cell count, hematocrit or 
packed cell volume, mean corpuscular volume, hemoglobin, white blood cell count, 
heterophils, band heterophils, eosinophils, lymphocytes, monocytes and thrombocyte counts.   
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The following serum biochemistry variables were determined: sodium, potassium, chloride, 
calcium, phosphate, magnesium, total protein, albumin, glucose, amylase, blood urea 
nitrogen, uric acid, alanine aminotransferase, aspartate aminotransferase, lactate 
dehydrogenase, gamma-glutamyl transferase, alkaline phosphatase, creatine kinase, total 
bilirubin, cholesterol and globulin. The following pheasant tissues were evaluated for gross 
and histopathologic changes that could be related to lasalocid administration: skin, eyes, 
liver, kidney, heart, lungs, trachea, adrenal gland, pancreas, esophagus, crop, spleen, 
proventriculus, ventriculus, intestines (upper, middle and cecum), bursa of fabricius, ovaries 
and oviducts, testes, bone, thyroid gland, thymus, parathyroid land, brain, spinal cord, 
pituitary body.  
Primary variables for statistical analyses were morbidity, mortality, live weights (beginning 
and ending pen weights), organ weights, hematology and serum biochemistry parameters, 
feed consumption and feed conversion rates. Statistical analyses were performed using SAS 
Enterprise Guide statistical software (version 4.3; SAS Institute, Inc., Cary, NC, USA). A 
mixed effect two-way analysis of variance (ANOVA) was performed on ending body 
weights, organ weights, hematology and serum chemistry data. “Individual pens” was 
considered the random effect. There were no additional random effects. Test group and sex, 
and the interaction of test group and sex were considered fixed effects. There were no 
additional fixed effects. Two-way ANOVA was used for feed consumption and feed 
conversion data. Least square means were used to compare the treated test groups to the 
control test groups. No adjustment of p-values was made. All statistical tests were conducted 
at 0.1 level of significance to meet the U.S Food and Drug Administration (FDA) protocol 
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specifications evaluating effects of lasalocid administration. Feed conversion rates were 
calculated in Microsoft© Excel©. No statistical analyses were made for necropsy and 
histopathology. 
Blinding was maintained such that no person having knowledge of the dosing was involved 
in the clinical evaluations, necropsies or histopathologic examinations. All phases of the 
study were approved by the Institutional Animal Care and Use Committee (IACUC) of Iowa 
State University, conducted under Good Laboratory Practices (GLP) (21 CFR Part 58) 
guidelines and critical phases were monitored by quality assurance personnel from the Minor 
Use Animal Drug Program (MAUDP), National Research Project-7 (NRSP-7). 
Results 
All groups of pheasants received their intended diets for the entire 6 weeks. Two out of 80 
pheasants (2.50%) died prior to study termination. Their deaths were not related to lasalocid 
administration. All other pheasants appeared to be in good health for the duration of the 
study. No significant differences were observed in live weights; overall feed consumption; 
feed conversion rates; clinical pathology parameters; or gross and histopathologic tissue 
evaluations when the treatment group was compared to controls. 
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Table 4. Test group diet analyses reported by Alpharma Inc. 
Diet 
Target dose  
g/t (ppm) 
Pre-trial lasalocid 
analysis 
g/t (ppm) 
Post-trial lasalocid 
analysis  
g/t (ppm) 
Control 0 <0.5 <0.5 
3X 340 (375) 302.4 (333) 378.0 (417) 
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Table 5. Test group means and standard deviations (SD) for live weights, absolute 
organ and weights overall feed consumption and feed conversion rates. 
Variable 
Control 3X Group 
Mean (SD) Mean (SD) 
Beginning body weight 81.25 (3.49) 80.88 (4.45) 
Ending body weight 369.51 (46.00) 362.79 (45.24) 
Feed consumption 3600.50 (328.10) 3546.50 (278.58) 
Feed conversion rate 2.10 (0.11) 2.11 (0.10) 
   
Liver weight 7.60 (0.91) 7.61 (1.16) 
Heart weight 2.10 (0.51) 2.06 (0.53) 
Spleen weight 0.35 (0.10) 0.31 (0.09) 
Thymus weight 1.20 (0.47) 1.15 (0.53 ) 
   
  
37 
 
Table 6. Test group means and standard deviations (SD) from clinical pathology sample 
testing performed in controls and pheasants treated with lasalocid sodium. 
Parameter (units) 
Control 3X Group 
Mean (SD) Mean (SD) 
RBC (x10
6
/µl) 2.64 (0.32) 2.46 (2.46) 
PCV (%) 33.33 (2.71) 33.13 (3.11) 
MCV (fl) 127.88 (16.03) 137.00 (18.39) 
WBC (x10
3
/µl) 9.99 (4.14) 8.90 (4.28) 
-Heterophils (x10
3
/µl) 1.79 (1.69) 1.35 (1.01) 
-Eosinophils (x10
3
/µl) 0.11 (0.11) 0.05 (0.11) 
-Basophils (x10
3
/µl) 0.37 (0.30) 0.36 (0.20) 
-Lymphocytes (x10
3
/µl) 7.36 (3.08) 6.78 (3.35) 
-Monocytes (x10
3
/µl) 0.30 (0.36) 0.37 (0.43) 
Glucose (mg/dl) 281.21 (21.23) 291.96 (22.13) 
TP (mg/dl) 2.87 (0.27) 2.90 (0.26) 
Albumin (mg/dl) 1.10 (0.12) 1.13 (0.12) 
Creatine kinase (IU/L) 5332.71 (2881.15) 6120.92 (2400.43) 
AST (IU/L) 397.13 (50.65) 422.21 (51.19) 
ALT (IU/L) 7.42 (3.87) 7.00 (1.84) 
GGT (IU/L) 10.04 (0.20) 10.04 (0.20) 
Calcium (mg/dl) 9.73 (0.48) 9.25 (1.78) 
Phosphorus (mg/dl) 7.56 (0.92) 7.25 (5.7-10.3) 
Sodium (mEq/L) 143.54 (2.21) 143.63 (1.76) 
Potassium (mEq/L) 3.69 (0.36) 3.46 (0.38) 
Chloride (mEq/L) 111.33 (1.74) 112.29 (2.07) 
Magnesium (mg/dl) 2.04 (0.22) 2.05 (0.16) 
Amylase (mg/dl) 447.00 (101.51) 420.39 (97.70) 
Uric Acid (mg/dl) 7.01 (4.59) 8.28 (3.59) 
LDH (IU/L) 3350.83 (644.82) 3783.38 (967.70) 
ALP (IU/L) 440.08 (65.41) 407.04 (101.06) 
Total Bilirubin (mg/dl) 0.10 (0.00) 0.10 (0.00) 
Cholesterol (mg/dl) 97.63 (13.11) 100.88 (17.05) 
Globulin (mg/dl) 2.03 (0.37) 2.03 (0.35) 
Variables: RBC, red blood cell; PCV,  packed cell volume; MCV, mean corpuscular volume; 
WBC, white blood cell; heterophils; eosinophils; lymphocytes; monocytes; glucose, T, total 
protein; albumin, creatine kinase; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; GGT, gamma-glutamyl transferase; calcium; phosphorous; sodium, 
potassium; chloride; magnesium; amylase; uric acid; LDH,  lactate dehydrogenase; ALP, 
alkaline phosphatase; total bilirubin, cholesterol and globulin 
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CHAPTER 4. REFERENCE INTERVALS FOR CLINIAL PATHOLOGY 
PARAMETERS FOR RING-NECKED PHEASANTS (PHASIANUS 
COLCHICUS) AT 6 WEEKS OF AGE 
Modified from a manuscript be submitted to the Journal for Avian Diseases 
Dzikamunhenga R.S., and Griffith R.W. 
Abstract 
The objective of this study was to determine and report reference intervals (RIs) for 
hematologic and serum biochemical parameters for ring-necked pheasants at 6 weeks of age. 
Data from one hundred and nineteen heparin and EDTA blood samples collected from 
clinically healthy Chinese ring-necked pheasants were available for statistical analyses. 
Reference intervals were generated in Microsoft® Excel® using Reference Value Advisor 
freeware. Ninety-five percent RIs were calculated using nonparametric methods following 
Clinical and Laboratory Standards Institute (CLSI) guidelines. These RIs will be useful for 
the monitoring of health and diagnosis of disease in confined pheasant populations.  
Introduction 
Hematology and serum biochemistry variables can be useful indicators of normal internal 
physiology or disease in animals and people. Reference intervals (RIs) are useful when 
clinical evaluation is based on analysis of multiple parameters. RIs for many species have 
been established and these continue to be updated according to changing population 
dynamics. Information regarding RIs for ring-necked pheasants is lacking with only selected 
clinical pathology parameters ever having been reported in literature. The objective of this 
study was to determine reference intervals for clinical pathology parameters in clinically 
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healthy pheasants at 6 weeks of age. These RIs were required so that values of clinical 
pathology parameters determined in 2 separate battery trials evaluating the safety of lasalocid 
and fenbendazole respectively in ring-necked pheasants could be compared to normal ranges. 
Materials and Methods 
Pheasants 
A posteriori sampling as described by CLSI C28-A3 was followed where inclusion and 
exclusion criteria were set after blood sampling (1, 7). One hundred and nineteen blood 
samples from clinically healthy ring-necked pheasants were available for analysis. Pheasants 
had been one-day old when they were acquired and approximately 6 weeks old, weighing 
between 281g and 492g when they were euthanized. They had been fed a non-medicated 
commercial basal diet, Game Startena
TM 
(Purina ®), for the entire duration. They had been 
raised five birds to a pen in floor pens measuring approximately 1.2 meters x 1.2 meters x 1.2 
meters at an Iowa State University poultry research facility. Each pheasant chick had been 
physically examined on day 0 and at 6 weeks of age. Pheasants were observed twice daily 
throughout the study to determine their general appearance as well as monitor consistency of 
fecal output, death and/or normal conditions.  Pheasant data was included if they had been 
determined to be clinically healthy at the time of euthanasia and excluded if they had shown 
obvious signs of disease prior to euthanasia. 
Blood collection and analytical methods 
Pheasants had been humanely euthanized via intramuscular injection of phenobarbital 
directly into the breast muscle. Approximately 1ml of blood was collected via the vena cava 
prior to cardiac arrest and placed in EDTA and heparinized vacutainer tubes for clinical 
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pathology analyses. Once collected, blood samples were placed on ice and submitted to Iowa 
State University, Veterinary Clinical Pathology Laboratory within one hour. Complete blood 
counts were performed by standard manual techniques for avian species using a 
hemacytometer and unopette (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, 
USA) and included red blood cell count, white blood cell count, packed cell volume, white 
blood cell count differential (based on 100 cells) including heterophils, eosinophils, 
lymphocytes and monocytes. Lipemic or hemolytic samples were not included.  Air-dried 
Wright-stained blood smears were evaluated for cellular morphology and thrombocyte 
estimates according to the standard operating procedure in the laboratory. Serum biochemical 
variables were analyzed using Hitachi 912 chemistry analyzer (Roche Diagnostics Corp, 
Indianapolis, IN, USA) or Ortho Vitros® 5.1 FS (Ortho-Clinical Diagnostics, Inc. Rochester, 
NY, USA) and included glucose, total protein; albumin, creatine kinase; aspartate 
aminotransferase; alanine aminotransferase, gamma-glutamyl transferase, calcium, 
phosphorous, sodium, potassium, chloride, magnesium, amylase, uric acid, lactate 
dehydrogenase, alkaline phosphatase, total bilirubin, cholesterol and globulin. 
Statistical Analyses 
Data were initially examined visually for obvious outliers, with a focus on retaining the 
values rather than deleting them, if not known to be aberrant observations, as recommended 
by CLSI for reference intervals. Pheasant RIs were generated in Microsoft© Excel© using 
reference value advisor freeware as described by Geffré et al. (21). Pheasant 95% reference 
intervals were calculated by nonparametric methods following CLSI guidelines, and 90% 
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confidence intervals (CI) were determined for lower and upper limits. Means, medians, 
standard deviations and 95% RIs were determined for all parameters. 
Results 
Data from 119 blood samples were used for statistical analyses. Hematology parameters 
could not be determined from 12 heparin tubes because these clotted prior to analyses. RBC 
and MCV were only reported for 84 samples. Outliers were identified in 5 biochemical 
samples (lactate dehydrogenase, 11,582 IU/L; 51,41I U/L; creatine kinase 14,163 IU/L and 
16,000 IU/L; aspartate aminotransferase 7,500 IU/L) and only these values were removed. 
Means, ranges, 95% RIs and 90% confidence intervals (CI) were determined for biochemical 
and hematologic variables for the pheasants are shown in Table 1. 
Discussion 
Using CLSI guidelines modified by the American Society of Clinical Veterinary Pathology 
(ASCVP), we were able to determine reference intervals for clinical pathology parameters in 
clinically healthy Chinese ring-neck pheasants at 6 weeks of age (1). Other reports available 
in the literature, describe selected clinical pathology parameters in terms of means and 
standard deviations (35, 56, 65) but do not report RIs that are more useful. We did not 
analyze males and females separately because at 6 weeks of age, pheasants are still juvenile 
and hormonal effects are likely to be minimal. Pheasants were considered clinically healthy if 
prior to euthanasia they had a normal appearance, were alert and obvious signs of disease 
including diarrhea or respiratory distress were absent. No medications were added to feed or 
water during the six weeks the pheasants were monitored that would otherwise affect clinical 
pathology parameters. Reports on gross and microscopic evaluations of individual birds were 
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available and analyzed in addition to the clinical pathology parameters. Pheasant tissues did 
not show any pathological changes that would otherwise influence determination of RIs. 
The values reported here are useful for making clinically relevant decisions in confined 
pheasant populations. However, several factors may account for variability reported by 
different clinical laboratories such as diet, husbandry, pre-analytical and analytical methods 
as well as other factors not evaluated here such as age, sex or season. Not only this but 
excitement and the physiologic response to handling may affect certain parameters such as 
leukocytes, creatine kinase and aspartate aminotransferase (13, 37).  We recommend caution 
when using these RIs for clinical decision-making or for transference and validation of RIs 
adopted from other sources. 
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Table 7: Hematology and serum biochemistry variables for Chinese ring-necked pheasants at 6 weeks of age. 
 
n Mean Median SD 
Range 
(Min – Max) 
95% RI 
90%CI for 
Lower Limit 
90% CI for 
Upper Limit 
Hematology parameter (units)         
RBC (x10
6
/µl) 84 2.83 2.81 0.45 1.9-5.2 1.99-3.60 1.93-2.17 3.39-5.18 
PCV (%) 107 34.5 35 3.2 23-41 28-40 23-29 39.3-41 
MCV (fl) 84 124.74 122.85 15.66 71.4-181.4 90.58-164.29 71.4-105.33 150.65-181.4 
WBC (x10
3
/µl) 107 11.67 11.1 5.71 2.2 – 29.9 2.84-26.44 2.19-4 23.05-29.92 
-Heterophils (x10
3
/µl) 107 2.31 1.71 2.24 0.2-13.9 0.24-9.16 0.17-0.37 6.74-13.88 
-Eosinophils (x10
3
/µl) 107 0.09 0 0.12 0.0-0.6 0-0.45 0-0 0.36-0.57 
-Basophils (x10
3
/µl) 107 0.61 0.48 0.54 0-3.2 0-2.24 0-0.09 1.71-3.24 
-Lymphocytes (x10
3
/µl) 107 8.4 7.73 4.65 1.3-24.8 2.02-21.39 1.26-2.72 17.24-24.83 
-Monocytes (x10
3
/µl) 107 0.3 0.21 0.33 0-1.6 0-1.3 0-0 0.99-1.62 
Serum biochemistry parameter (units)       
Glucose (mg/dl) 119 312 311 42.6 191-396 208-386 191-241 376-396 
Total protein (gm/dl) 119 2.92 2.9 0.26 2.2-3.8 2.4-3.4 2.2-2.5 3.3-3.8 
Albumin (gm/dl) 119 1.33 1.4 0.21 1-1.8 1-1.7 1-1 1.6-1.8 
Creatine kinase (IU/L) 116 3903.4 3935 1601 256-9001 978-7352.5 256-1464.6 6506.8-9001 
AST (IU/L) 118 400.7 381.5 94.4 240-922 285-689.3 240-304.8 622.2-922 
ALT (IU/L) 119 8.2 6 6.6 4-42 4-31 4-4 23-42 
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Table 8. (continued) 
 
n Mean Median SD 
Range 
(Min – Max) 
95% RI 
90%CI for 
Lower Limit 
90% CI for 
Upper Limit 
GGT (IU/L) 119 6.4 6 3.3 0-12 1-10 0-1 10.12 
Calcium (mg/dl) 119 9.96 10 0.6 7.6-11.7 8.4-11.1 7.6-9.1 10.9-11.7 
Phosphorus (mg/dl) 119 8.84 8.6 1.66 6.3 6.4-13.3 6.3-6.5 12-15.7 
Sodium (mEq/L) 119 150.2 151 5.7 138-165 142-161 138-142 159-165 
Potassium (mEq/L) 119 4.07 3.7 1.75 2-15.5 2.3-10.7 2-2.6 6.5-15.5 
Chloride (mEq/L) 119 112.3 112 2.5 106-120 108-118 106-109 116-120 
Magnesium (mg/dl) 119 2.4 2.37 0.35 1.8-3.9 1.82-3 1.78-1.91 2.97-3.94 
Amylase (IU/L) 118 1702.6 1863 1244 24.3-5141 
221.63-
4168.2 
24.27-295.7 3781.3-5141 
Uric acid (mg/dl) 119 13.22 12 8.07 3.5-45 3.9-34.7 3.5-4.1 29.8-45 
LDH (IU/L) 118 2019 983 1492 505-5413 534-5340 505-597 4595-5413 
ALP (IU/L) 119 949.4 1039 502.3 106-2006 317-1815 106-332 1752-2006 
Total bilirubin (mg/dl) 119 0.21 0.15 0.16 0-0.9 0.07-0.69 0.04-0.1 0.54-0.88 
Cholesterol (mg/dl) 119 109.6 109 17.3 69-150 81-140 69-83 135-150 
Globulin (mg/dl) 119 1.66 1.6 0.36 1-2.8 1-2.6 1-1.2 2.4.2.8 
Variables: RBC, red blood cell; PCV,  packed cell volume; MCV, mean corpuscular volume; WBC, white blood cell; heterophils; eosinophils; 
lymphocytes; monocytes; glucose, TP, total protein; albumin, creatine kinase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, 
gamma-glutamyl transferase; calcium; phosphorous; sodium, potassium; chloride; magnesium; amylase; uric acid; LDH,  lactate dehydrogenase; ALP, 
alkaline phosphatase; total bilirubin, cholesterol and globulin 
1. All 90% CIs exceeded those recommended by the IFCC in CLSI C28-A3. 
2. CI indicates confidence interval. 
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CHAPTER 5. DISCUSSION 
Coccidiosis remains a major concern for the welfare of farm raised ring-necked pheasants 
and their producers. The intestinal damage impairs essential nutrient and water absorption 
leading to diarrhea, poor weight gain, dehydration and frequently death. The anaerobic 
environment created favors the proliferation of Clostridium perfringens Type A, that causes 
necrotic enteritis. Clostridial diarrhea may be poorly responsive to treatment because 
pheasants are too ill to drink medicated water; and mortality is usually 100%. The impaired 
feed conversion means pheasants consume more feed per pound of weight gain compared to 
uninfected birds. They take longer to attain market weight causing pheasant farmers to suffer 
huge economic losses since the cost of feed can be about 75% of the operation.  
 
Several risk factors predispose farmed ring-necked pheasants to coccidiosis. Wet litter, poor 
ventilation, and contaminated drinkers and feeders favor oocyst sporulation and ingestion.  
Growing pheasants are often reared in net-covered pens and the soil in those pens can 
become heavily contaminated with coccidia. Improper mixing of coccidiostat with feed and 
inadequate medicated feed consumption will favor high parasite multiplication within the 
host and increase oocyst shedding. Stressors such as concurrent diseases or overcrowding 
may further exacerbate disease because the immune system is impaired. Multiple species of 
Eimeria are usually isolated from clinical outbreaks of disease (23). Because species are site 
specific, this may account for the varying degrees of diarrhea and intestinal lesions seen in 
clinically affected birds. While it is generally believed that the number of oocysts ingested is 
directly proportional to the intensity of the disease, it has been shown experimentally that a 
high number of oocysts of less pathogenic species, such as E. duodenalis, may actually need 
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to be ingested before clinical diarrhea occurs (24). It has never been determined whether, the 
acidic pH, enzymatic activity and high ingesta transit in the proximal intestine may be the 
reason why long term parasite survival is not favorable in the upper gastrointestinal tract 
compared to the lower intestine where the more virulent species, E. colchici and E. phasiani, 
attach.  
 
Eradication of coccidia on pheasant farms is difficult because of the long term oocyst 
survival in the environment. Since pheasants are gallinaceous birds, similar to other birds in 
anatomy, physiology and some disease aspects, it is reasonable to assume that medications 
such as lasalocid, used in chickens and turkeys can be applied clinically, in ring-necked 
pheasants. The mechanism of action of lasalocid against coccidia has already been described 
(19). It achieves serum levels rapidly in chickens although about 95% remains in the 
intestines and is excreted in feces. It is active against extracellular stages of coccidia, 
reducing the severity of diarrhea, dehydration and oocyst shedding. Clinical efficacy against 
Eimeria species causing disease in ring-necked pheasants has been established at 120 ppm 
(16, 42). In comparison, clinical efficacy was established in other poultry species between 
68-125 ppm. No reports are available that demonstrate that lasalocid would be efficacious for 
pheasant coccidia at lower doses. If approved, users would be encouraged to adhere to the 
recommendation of 125 ppm unless scientific data is provided that lasalocid can be effective 
at reduced doses. This is because, treating at lower doses would be extra-label, likely non-
therapeutic and could result in emergence of resistant strains and subsequent failure of 
lasalocid therapy.  
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The objective of the work here was to assess the safety of lasalocid when given to ring-
necked pheasants at 1, 2 and 3 times the recommended high dose of lasalocid in other species 
of poultry for six weeks which is equivalent to three times the normal treatment length. This 
was data required by the FDA/CVM in partial fulfillment of the NADA requirement for 
adding ring-pheasants to the Avatec® drug label. Most trials reported in literature that 
involve lasalocid toxicity in avian species examine feed intake, feed conversion, clinical 
behavior and oocyst shedding. In our study, we evaluated additional parameters including 
clinical pathology parameters, as well as gross and microscopic tissue changes.  
 
Hematology and serum biochemistry changes following lasalocid administration in ring-
necked pheasants have never been reported. Because Na
+
, K
+
, H
+
, Ca
2+
 and Mg
2+ 
are 
preferentially transported across cell membranes, it is reasonable to assume that these 
parameters may be decreased in serum (18). Since cardiac muscle, skeletal muscle and the 
liver have been reported to be sensitive to lasalocid in other avian species, serum enzyme 
elevations may be observed for creatine kinase, aspartate aminotransferase and lactate 
dehydrogenase. Even if these changes are observed, they would still need to be compared 
against established reference ranges. Unfortunately, reference intervals for clinical pathology 
parameters are lacking for ring-necked pheasants. Furthermore, pheasants like other game 
birds, are highly excitable and the stress and physiologic effects of handling can falsely affect 
clinical pathology data. Minimal muscle damage such as that occurring upon intramuscular 
injection of the phenobarbital  prior to blood collection, can elevate serum levels of aspartate 
aminotransferase and lactate dehydrogenase enzymes (37). We therefore interpreted the 
hemograms and clinical chemistry panels cautiously. 
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We established reference intervals for pheasant clinical pathology parameters at six weeks of 
age using statistically acceptable methods (Chapter 4). We observed several values that 
would be considered elevated in mammalian and other avian species, for white blood cells 
counts, creatine kinase, alkaline phosphatase and lactate dehydrogenase.  These were not 
associated with any obvious clinical observations or tissue changes. The observations made 
in the first trial where males had significantly higher monocyte counts, serum total protein 
and calcium levels and significantly lower serum alkaline phosphatase enzyme levels and red 
blood cell counts were considered incidental. This is because they did not appear to be dose 
related, were not repeatable in the second trial, were within reference ranges and were of 
such small magnitude that they were considered negligible.  
 
Lasalocid-associated tissue changes following lasalocid toxicity have been reported for 
chickens, turkeys and ruminants (12, 20, 23) but not for pheasants. Cardiac and skeletal 
muscles are the most consistently affected although liver enlargement and ascites have been 
reported. The significance of the single pheasant heart that had changes suggestive of 
lasalocid toxicity could not be determined at this time. The pheasant weighed 316 g (range 
for the group was 197-467 g), was clinically normal, its clinical pathology variables were 
within the reference ranges and no other gross tissue or microscopic lesions were observed. 
The possibility that this could be an early case of toxicity cannot be ruled out but, because no 
other pheasants were observed with similar lesions, the lesions in this bird could have been 
incidental.   
Lasalocid has been used on pheasant farms in an extra-label manner for the last 2 decades 
and is effective against pheasant specific Eimeria (16, 42). When its efficacy was first 
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demonstrated in 1987, lasalocid was not routinely used on pheasant farms.  Eimeria isolates 
used in the study were likely naïve to lasalocid although isolates tested were only collected 
from a single farm.  The isolates also did not include E. colchici, which is believed to be the 
most pathogenic of all the species. When its efficacy was evaluated by Fuller et al, 2008, 
isolates not only came from 2 geographically separate areas, but included E. colchici. While 
Fuller et al., did not observe the same efficacy as McQuistion, against E. phasiani, it is 
possible that the concurrent infection with E. colchici could have masked the true efficacy of 
lasalocid. Although it is reasonable to assume that resistance to lasalocid may be emerging 
because of its extra-label use on farms over the last 20 years, the true effect of ELDU of 
lasalocid would need to be investigated using molecular techniques such as PCR to identify 
the presence of lasalocid resistance genes in coccidia. However, using data from this study, 
and information published on efficacy, lasalocid can be used judiciously at 120 ppm and 
delay the occurrence of resistant strains.  
 
Although, ELDU of Avatec has become routine for controlling coccidiosis on pheasant 
farms, it should not replace good husbandry and biosecurity measures for all personnel 
involved in the care of pheasants or the facilities in which they are housed. Because oocysts 
can survive in the environment and on shoes, boots, vehicle wheels and clothing, good 
sanitation, proper drainage, decreasing stocking density and all in- all out practices may 
disrupt the life cycle of pheasant coccidia and lessen the occurrence of disease. Other 
therapies, reported in literature may be useful against coccidiosis in pheasants. Diclazuril at 2 
ppm and 4 ppm has been described to be effective against E. colchici, E. phasiani and E. 
duodenalis  (71). Treatment of E. colchici with ozone  has been shown to inhibit sporulation 
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and reduce infectivity but it is likely to be impractical and expensive to implement (34). The 
possibility of vaccination against Eimeria species has been explored but its efficacy is 
unknown at this time.  
 
In conclusion, physical, clinical pathologic and tissue evaluations were similar between 
control and lasalocid treated pheasants. The no-observed-effect-level (NOEL) for lasalocid 
sodium 20% when administered orally for six weeks was determined to be 375 ppm.   
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CHAPTER 6. GENERAL CONCLUSIONS AND FUTURE WORK 
The work presented here was a target animal safety evaluation required for FDA/CVM 
review towards adding ring-necked pheasants to the Avatec® label. We were able to show 
that Avatec fed at up to three times the recommended high dose in other avian species, at 
three times the normal treatment duration, resulted in no changes in feed consumption, feed 
conversion, and weight gain attributable to lasalocid treatment. We also evaluated additional 
parameters, i.e. clinical pathology variables and gross necropsy and histopathology tissue 
sections. No adverse effects associated with lasalocid treatment were observed in any of 
these additional parameters. This target animal safety data has been submitted and is under 
review by FDA/CVM.  Data involving lasalocid efficacy has already been established and 
reported. Additional studies to evaluate consumer and environmental safety remain.  
 
High performance liquid chromatography (HPLC) is the method used to detect lasalocid 
residues in chicken and turkey tissues. Before it can be applied to pheasants, FDA/CVM 
requires this technique be bridged for use in pheasant tissues. The goal of determining human 
food safety would be to determine adequate Avatec withdrawal periods; otherwise lasalocid 
could end up in human food chain. Tissue residues for lasalocid have been described for 
chicken and turkey tissues.  Lasalocid is approved for a zero-day withholding period for 
other avian species primarily because the vast majority of the drug remains in the intestine 
and is not found in the edible tissues.  The FDA/CVM would require that lasalocid in 
pheasant edible tissues should not exceed the levels described for chickens and turkeys. 
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Lastly information regarding environmental and user safety of lasalocid would need to be 
reviewed by FDA/CVM. Because, no changes in manufacturing, storage or distribution are 
being advocated, controlled trials are not warranted to demonstrate environmental or user 
safety. Material submitted to FDA/CVM will be extrapolated from assessments done in 
chickens and turkeys since conditions of use are likely to be similar. 
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